Annexon (ANNX) reported "rapid recovery and durable benefit" for patients in the phase 3 trial of tanruprubart, a potential targeted therapy for Guillain-Barre Syndrome,
The trial showed a 2.4-fold higher likelihood of improvement at week eight versus placebo in 241 patients, the company said Tuesday in a statement, with the results presented at the American Academy of Neurology annual meeting in San Diego.
Key findings showed that tanruprubart led to a 14-fold improvement in mobility at week one and twice as many patients had no limitations by week 26, the company said.
Shares of the company rose 3.3% in recent after-hours trading, paring earlier gains.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.